Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Pulse Biosciences ( (PLSE) ) is now available.
On December 9, 2025, Pulse Biosciences, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, stockholders elected six directors to serve until the 2026 meeting, ratified Deloitte & Touche LLP as the independent accounting firm for 2025, approved executive compensation, and decided to hold future advisory votes on executive compensation every three years.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. operates in the medical technology industry, focusing on developing innovative bioelectric medicine solutions. The company is known for its proprietary Nano-Pulse Stimulation technology, which is designed to treat a variety of medical conditions.
Average Trading Volume: 182,218
Technical Sentiment Signal: Sell
Current Market Cap: $962.3M
For an in-depth examination of PLSE stock, go to TipRanks’ Overview page.